JP2008546811A - 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 - Google Patents
病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 Download PDFInfo
- Publication number
- JP2008546811A JP2008546811A JP2008518575A JP2008518575A JP2008546811A JP 2008546811 A JP2008546811 A JP 2008546811A JP 2008518575 A JP2008518575 A JP 2008518575A JP 2008518575 A JP2008518575 A JP 2008518575A JP 2008546811 A JP2008546811 A JP 2008546811A
- Authority
- JP
- Japan
- Prior art keywords
- agonists
- mas
- protein
- peptides
- coupled receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 57
- 230000002265 prevention Effects 0.000 title claims abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 39
- 230000000694 effects Effects 0.000 title claims abstract description 30
- 201000010099 disease Diseases 0.000 title claims abstract description 21
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 15
- 238000011160 research Methods 0.000 title claims abstract description 7
- 229940044601 receptor agonist Drugs 0.000 title claims description 6
- 239000000018 receptor agonist Substances 0.000 title claims description 6
- 229940044551 receptor antagonist Drugs 0.000 title description 3
- 239000002464 receptor antagonist Substances 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 79
- 229940123344 GPR antagonist Drugs 0.000 claims abstract description 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 61
- 229940080349 GPR agonist Drugs 0.000 claims abstract description 58
- 108010021281 angiotensin I (1-7) Proteins 0.000 claims abstract description 57
- 108091008611 Protein Kinase B Proteins 0.000 claims abstract description 54
- 239000005557 antagonist Substances 0.000 claims abstract description 42
- 210000000056 organ Anatomy 0.000 claims abstract description 39
- 239000000556 agonist Substances 0.000 claims abstract description 38
- 210000001519 tissue Anatomy 0.000 claims abstract description 26
- 230000001640 apoptogenic effect Effects 0.000 claims abstract description 23
- 230000001684 chronic effect Effects 0.000 claims abstract description 14
- 230000009467 reduction Effects 0.000 claims abstract description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 6
- 230000004075 alteration Effects 0.000 claims abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 7
- 238000002054 transplantation Methods 0.000 claims abstract 7
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract 6
- 230000001052 transient effect Effects 0.000 claims abstract 2
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims description 73
- 108050004181 Proto-oncogene Mas Proteins 0.000 claims description 54
- 102000015925 Proto-oncogene Mas Human genes 0.000 claims description 52
- 241001465754 Metazoa Species 0.000 claims description 16
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 15
- 201000001881 impotence Diseases 0.000 claims description 15
- 208000017169 kidney disease Diseases 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 13
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 13
- 238000001990 intravenous administration Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 208000020358 Learning disease Diseases 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 10
- 230000008694 endothelial dysfunction Effects 0.000 claims description 10
- 238000007918 intramuscular administration Methods 0.000 claims description 10
- 201000003723 learning disability Diseases 0.000 claims description 10
- 208000010125 myocardial infarction Diseases 0.000 claims description 10
- 238000007920 subcutaneous administration Methods 0.000 claims description 10
- 230000000699 topical effect Effects 0.000 claims description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
- 208000026139 Memory disease Diseases 0.000 claims description 9
- 201000000585 muscular atrophy Diseases 0.000 claims description 9
- 230000021595 spermatogenesis Effects 0.000 claims description 9
- 230000003412 degenerative effect Effects 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
- 206010019280 Heart failures Diseases 0.000 claims description 7
- 206010028289 Muscle atrophy Diseases 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 7
- 230000020763 muscle atrophy Effects 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 208000015114 central nervous system disease Diseases 0.000 claims description 6
- 230000002093 peripheral effect Effects 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 206010006895 Cachexia Diseases 0.000 claims description 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 5
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 210000004204 blood vessel Anatomy 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 210000004996 female reproductive system Anatomy 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 230000007774 longterm Effects 0.000 claims description 5
- 210000004995 male reproductive system Anatomy 0.000 claims description 5
- 230000035800 maturation Effects 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 5
- 238000011069 regeneration method Methods 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 claims description 3
- -1 acyclic oligosaccharide Chemical class 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000011859 microparticle Substances 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920002988 biodegradable polymer Polymers 0.000 claims description 2
- 239000004621 biodegradable polymer Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims 21
- 230000032683 aging Effects 0.000 claims 18
- 208000035475 disorder Diseases 0.000 claims 18
- 239000008280 blood Substances 0.000 claims 9
- 210000004369 blood Anatomy 0.000 claims 9
- 208000014951 hematologic disease Diseases 0.000 claims 9
- 201000004384 Alopecia Diseases 0.000 claims 8
- 206010015150 Erythema Diseases 0.000 claims 8
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 8
- 231100000360 alopecia Toxicity 0.000 claims 8
- 231100000321 erythema Toxicity 0.000 claims 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 206010052428 Wound Diseases 0.000 claims 7
- 208000027418 Wounds and injury Diseases 0.000 claims 7
- 230000001154 acute effect Effects 0.000 claims 7
- 238000001959 radiotherapy Methods 0.000 claims 7
- 208000037803 restenosis Diseases 0.000 claims 7
- 230000019100 sperm motility Effects 0.000 claims 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 6
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 6
- 201000006370 kidney failure Diseases 0.000 claims 6
- 201000001320 Atherosclerosis Diseases 0.000 claims 5
- 206010010904 Convulsion Diseases 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 208000014181 Bronchial disease Diseases 0.000 claims 4
- 206010071602 Genetic polymorphism Diseases 0.000 claims 4
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 4
- 230000013020 embryo development Effects 0.000 claims 4
- 238000001415 gene therapy Methods 0.000 claims 4
- 230000006872 improvement Effects 0.000 claims 4
- 230000000302 ischemic effect Effects 0.000 claims 4
- 201000001119 neuropathy Diseases 0.000 claims 4
- 230000007823 neuropathy Effects 0.000 claims 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- 208000023504 respiratory system disease Diseases 0.000 claims 4
- 230000037380 skin damage Effects 0.000 claims 4
- 208000037905 systemic hypertension Diseases 0.000 claims 4
- 208000019838 Blood disease Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims 3
- 230000035935 pregnancy Effects 0.000 claims 3
- 208000017443 reproductive system disease Diseases 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-methyl-PhOH Natural products CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims 1
- 206010070538 Gestational hypertension Diseases 0.000 claims 1
- 239000012981 Hank's balanced salt solution Substances 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims 1
- 229940093471 ethyl oleate Drugs 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 239000002687 nonaqueous vehicle Substances 0.000 claims 1
- 239000000346 nonvolatile oil Substances 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000008159 sesame oil Substances 0.000 claims 1
- 235000011803 sesame oil Nutrition 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims 1
- 229940033663 thimerosal Drugs 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- 230000037361 pathway Effects 0.000 description 17
- 230000026731 phosphorylation Effects 0.000 description 17
- 238000006366 phosphorylation reaction Methods 0.000 description 17
- 210000002216 heart Anatomy 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000036454 renin-angiotensin system Effects 0.000 description 11
- 102000038030 PI3Ks Human genes 0.000 description 10
- 108091007960 PI3Ks Proteins 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 101800000733 Angiotensin-2 Proteins 0.000 description 9
- 102400000345 Angiotensin-2 Human genes 0.000 description 9
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 9
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 9
- 229950006323 angiotensin ii Drugs 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004722 NADPH Oxidases Human genes 0.000 description 7
- 108010002998 NADPH Oxidases Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 6
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 210000001550 testis Anatomy 0.000 description 6
- 102000008873 Angiotensin II receptor Human genes 0.000 description 5
- 108050000824 Angiotensin II receptor Proteins 0.000 description 5
- 230000002424 anti-apoptotic effect Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 102000015427 Angiotensins Human genes 0.000 description 4
- 108010064733 Angiotensins Proteins 0.000 description 4
- 208000014644 Brain disease Diseases 0.000 description 4
- 101100520033 Dictyostelium discoideum pikC gene Proteins 0.000 description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000008753 endothelial function Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003746 Insulin Receptor Human genes 0.000 description 3
- 108010001127 Insulin Receptor Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 3
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 3
- 229940123073 Angiotensin antagonist Drugs 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101001112229 Homo sapiens Neutrophil cytosol factor 1 Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 102100023620 Neutrophil cytosol factor 1 Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 2
- 101710178372 Prolyl endopeptidase Proteins 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 206010058156 Reperfusion arrhythmia Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 210000002403 aortic endothelial cell Anatomy 0.000 description 2
- 230000000923 atherogenic effect Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000003372 endocrine gland Anatomy 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101150059573 AGTR1 gene Proteins 0.000 description 1
- 230000007730 Akt signaling Effects 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102400000347 Angiotensin 1-7 Human genes 0.000 description 1
- QMMRCKSBBNJCMR-KMZPNFOHSA-N Angiotensin III Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(C)C)C1=CC=C(O)C=C1 QMMRCKSBBNJCMR-KMZPNFOHSA-N 0.000 description 1
- QSBGWDDCOJYQGY-KOQODJNWSA-N Angiotensin IV Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)C(C)C)C1=CC=C(O)C=C1 QSBGWDDCOJYQGY-KOQODJNWSA-N 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 102400000348 Angiotensin-3 Human genes 0.000 description 1
- 101800000738 Angiotensin-3 Proteins 0.000 description 1
- 102400000349 Angiotensin-4 Human genes 0.000 description 1
- 101800000737 Angiotensin-4 Proteins 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102100025620 Cytochrome b-245 light chain Human genes 0.000 description 1
- 101710190086 Cytochrome b-245 light chain Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000022471 Fetal disease Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 1
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 description 1
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000006478 Protein Phosphatase 2 Human genes 0.000 description 1
- 108010058956 Protein Phosphatase 2 Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- HVYLDJKDVOOTHV-UHFFFAOYSA-N acetic acid;2-iminoethanethiol Chemical compound CC(O)=O.CC(O)=O.SCC=N HVYLDJKDVOOTHV-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 108010028321 angiotensin II (1-5) Proteins 0.000 description 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000009949 anti-apoptotic pathway Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000035581 baroreflex Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 210000005263 caudal ventrolateral medulla Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000001169 hypoglossal nerve Anatomy 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940127264 non-peptide agonist Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000003814 preoptic area Anatomy 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003244 pro-oxidative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009757 proliferative dysfunction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000034563 regulation of cell size Effects 0.000 description 1
- 230000037195 reproductive physiology Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000005262 rostral ventrolateral medulla Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001679 solitary nucleus Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000004377 supraoptic nucleus Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0502497-8A BRPI0502497A (pt) | 2005-06-28 | 2005-06-28 | uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças |
| PCT/BR2006/000125 WO2007000036A2 (en) | 2005-06-28 | 2006-06-28 | Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013000248A Division JP2013075911A (ja) | 2005-06-28 | 2013-01-04 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008546811A true JP2008546811A (ja) | 2008-12-25 |
| JP2008546811A5 JP2008546811A5 (https=) | 2009-08-20 |
Family
ID=37595483
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008518575A Withdrawn JP2008546811A (ja) | 2005-06-28 | 2006-06-28 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
| JP2013000248A Pending JP2013075911A (ja) | 2005-06-28 | 2013-01-04 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
| JP2017036611A Pending JP2017114901A (ja) | 2005-06-28 | 2017-02-28 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓ ｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013000248A Pending JP2013075911A (ja) | 2005-06-28 | 2013-01-04 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
| JP2017036611A Pending JP2017114901A (ja) | 2005-06-28 | 2017-02-28 | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓ ｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080312129A1 (https=) |
| EP (1) | EP1904087A2 (https=) |
| JP (3) | JP2008546811A (https=) |
| CN (1) | CN101247818A (https=) |
| BR (1) | BRPI0502497A (https=) |
| CA (1) | CA2613126A1 (https=) |
| WO (1) | WO2007000036A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015532291A (ja) * | 2012-10-02 | 2015-11-09 | タリックス ファーマシューティカルズ リミテッド | 脳状態の処置におけるアンジオテンシン |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0602366B1 (pt) | 2006-04-26 | 2017-12-12 | Universidade Federal De Minas Gerais | Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications |
| WO2008052295A1 (en) * | 2006-10-30 | 2008-05-08 | Universidade Federal De Minas Gerais | Process for the preparation of compounds of at1 receptor antagonists with angiotensin-(1-7), analogues thereof and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products |
| WO2008089532A1 (en) * | 2007-01-26 | 2008-07-31 | Universidade Federal De Minas Gerais - Ufmg | Pharmaceutical compositions and methods for treating erectile dysfunction |
| BRPI0800585B8 (pt) | 2008-02-13 | 2021-05-25 | Univ Minas Gerais | composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) |
| EP2163259B1 (en) | 2008-09-12 | 2012-06-13 | Charité-Universitätsmedizin Berlin (Charité) | Use of an Ang-(1-7) receptor agonist in acute lung injury |
| DE102009013456A1 (de) * | 2009-03-18 | 2010-09-23 | GÖPFERICH, Achim, Prof. Dr. | Nanopartikel für die Erkennung von Zellen, durch Bindung an G-Protein gekoppelte Rezeptoren |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| KR20140140546A (ko) * | 2012-02-10 | 2014-12-09 | 타릭스 파마슈티컬스 엘티디. | 말초 혈관 질환의 치료를 위한 조성물 및 방법 |
| US8557958B1 (en) | 2012-06-18 | 2013-10-15 | Tarix Pharmaceuticals Ltd. | Compositions and methods for treatment of diabetes |
| BR132012028005E2 (pt) * | 2012-10-31 | 2014-11-18 | Univ Minas Gerais | Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares. |
| JP6254692B2 (ja) * | 2013-07-03 | 2017-12-27 | ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ | 認知機能不全を治療するための方法 |
| US9333233B2 (en) | 2014-02-25 | 2016-05-10 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the delayed treatment of stroke |
| US9796759B2 (en) | 2014-07-21 | 2017-10-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides and methods for using and producing the same |
| US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
| CN113207799B (zh) * | 2021-03-19 | 2022-03-15 | 中山大学 | 一种二型糖尿病小鼠快速心衰模型的构建方法 |
| EP4371556A1 (en) | 2022-11-15 | 2024-05-22 | Explicat Pharma GmbH | Angiotensin(1-7) pharmaceutical compositions for inhalation |
| CN116355856A (zh) * | 2023-04-19 | 2023-06-30 | 陕西慧康生物科技有限责任公司 | 一种人mas1过表达细胞株及其构建方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030203834A1 (en) * | 2002-02-27 | 2003-10-30 | Tallant E. Ann | Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth |
| JP2004516036A (ja) * | 2000-12-22 | 2004-06-03 | アストラゼネカ・アクチエボラーグ | Ｍａｓ受容体に結合するダイノルフィンａのアゴニストまたはアンタゴニストを分析する方法 |
| JP2005511577A (ja) * | 2001-11-05 | 2005-04-28 | ユニベルシダデ フェデラル デ ミナス ジェライス − ユーエフエムジー | シクロデキストリン、リポソーム及び生分解性ポリマー並びに／或いはそれらの混合物及び生成物を用いる、ペプチドアンギオテンシン−（１−７）並びにその類似体、作動薬及び拮抗薬の製剤の調製方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6989363B1 (en) * | 1997-12-11 | 2006-01-24 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| US6548302B1 (en) * | 1998-06-18 | 2003-04-15 | Johns Hopkins University School Of Medicine | Polymers for delivery of nucleic acids |
| US6236766B1 (en) * | 1998-09-11 | 2001-05-22 | General Electric Company | Method and apparatus for zooming digital images |
| EP1117426B1 (en) * | 1998-10-02 | 2005-12-07 | Caritas St. Elizabeth's Medical Center of Boston, Inc. | Akt compositions for enhancing survival of cardiomyocytes |
| WO2000023100A2 (en) * | 1998-10-22 | 2000-04-27 | Curagen Corporation | Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| WO2000061141A2 (en) * | 1999-04-09 | 2000-10-19 | Au Jessie L S | Methods and compositions for enhancing delivery of therapeutic agents to tissues |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| WO2000071584A1 (en) * | 1999-05-20 | 2000-11-30 | Human Genome Sciences, Inc. | Seven transmembrane receptor genes |
| EP1268783B9 (en) * | 2000-03-29 | 2007-01-17 | Beth Israel Deaconess Medical Center, Inc. | Antiangiogene Eigenschaften von Matin und Fragmenten oder Varianten davon |
| JP2003532623A (ja) * | 2000-06-30 | 2003-11-05 | バイエル アクチェンゲゼルシャフト | 抗脈管形成性アンジオテンシン−７およびそれをコードするポリヌクレオチドを使用することによる脈管形成の調節方法 |
| WO2006005470A2 (en) * | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge) |
| BRPI0503122A (pt) * | 2005-05-30 | 2007-05-02 | Univ Minas Gerais | composições farmacêuticas do peptìdeo angiotensina-(1-7) [ang-(1-7)] e seus análogos, agonistas e antagonistas usando as ciclodextrinas, seus derivados, e o polìmeros biodegradáveis e/ou dos produtos derivados para uso no controle das funções do sistema reprodutivo |
-
2005
- 2005-06-28 BR BRPI0502497-8A patent/BRPI0502497A/pt not_active Application Discontinuation
-
2006
- 2006-06-28 CA CA002613126A patent/CA2613126A1/en not_active Abandoned
- 2006-06-28 WO PCT/BR2006/000125 patent/WO2007000036A2/en not_active Ceased
- 2006-06-28 CN CNA2006800302306A patent/CN101247818A/zh active Pending
- 2006-06-28 US US11/922,949 patent/US20080312129A1/en not_active Abandoned
- 2006-06-28 EP EP06741348A patent/EP1904087A2/en not_active Withdrawn
- 2006-06-28 JP JP2008518575A patent/JP2008546811A/ja not_active Withdrawn
-
2013
- 2013-01-04 JP JP2013000248A patent/JP2013075911A/ja active Pending
-
2017
- 2017-02-28 JP JP2017036611A patent/JP2017114901A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004516036A (ja) * | 2000-12-22 | 2004-06-03 | アストラゼネカ・アクチエボラーグ | Ｍａｓ受容体に結合するダイノルフィンａのアゴニストまたはアンタゴニストを分析する方法 |
| JP2005511577A (ja) * | 2001-11-05 | 2005-04-28 | ユニベルシダデ フェデラル デ ミナス ジェライス − ユーエフエムジー | シクロデキストリン、リポソーム及び生分解性ポリマー並びに／或いはそれらの混合物及び生成物を用いる、ペプチドアンギオテンシン−（１−７）並びにその類似体、作動薬及び拮抗薬の製剤の調製方法 |
| US20030203834A1 (en) * | 2002-02-27 | 2003-10-30 | Tallant E. Ann | Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015532291A (ja) * | 2012-10-02 | 2015-11-09 | タリックス ファーマシューティカルズ リミテッド | 脳状態の処置におけるアンジオテンシン |
| JP2018090625A (ja) * | 2012-10-02 | 2018-06-14 | タリックス ファーマシューティカルズ リミテッド | 脳状態の処置におけるアンジオテンシン |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013075911A (ja) | 2013-04-25 |
| WO2007000036A3 (en) | 2007-05-18 |
| US20080312129A1 (en) | 2008-12-18 |
| BRPI0502497A (pt) | 2007-02-06 |
| WO2007000036A2 (en) | 2007-01-04 |
| CA2613126A1 (en) | 2007-01-04 |
| JP2017114901A (ja) | 2017-06-29 |
| EP1904087A2 (en) | 2008-04-02 |
| CN101247818A (zh) | 2008-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017114901A (ja) | 病気の研究、予防及び治療のためのアポトーシス活性調節剤としての、ｍａｓ ｇ−タンパク質結合受容体アゴニスト及びアンタゴニストの使用 | |
| Paul et al. | Physiology of local renin-angiotensin systems | |
| Dinh et al. | Angiotensin receptors: distribution, signalling and function | |
| Bader et al. | Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research | |
| Xu et al. | ACE2/ANG-(1–7)/Mas pathway in the brain: the axis of good | |
| Gutkowska et al. | Oxytocin revisited: its role in cardiovascular regulation | |
| François et al. | Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition | |
| Adiarto et al. | ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy | |
| EP1158998B1 (en) | Use of neuregulin for manipulating cardiac muscle function | |
| Cao et al. | Increased calpain-1 in mitochondria induces dilated heart failure in mice: role of mitochondrial superoxide anion | |
| Pagliaro et al. | Rethinking the renin-angiotensin system and its role in cardiovascular regulation | |
| Boccalini et al. | Relaxin protects cardiac muscle cells from hypoxia/reoxygenation injury: involvement of the Notch‐1 pathway | |
| McCollum et al. | Angiotensin-(1–7) abrogates mitogen-stimulated proliferation of cardiac fibroblasts | |
| Chen et al. | Inhibition of TGF-β1 signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through angiogenesis and reduction of apoptosis | |
| Steckelings et al. | The Renin—Angiotensin—Aldosterone System | |
| Sun et al. | Crosstalk between endothelial cell-specific calpain inhibition and the endothelial-mesenchymal transition via the HSP90/Akt signaling pathway | |
| Gutkowska et al. | Oxytocin revisited: It is also a cardiovascular hormone | |
| Xiang et al. | Cardiomyocyte-specific overexpression of human stem cell factor protects against myocardial ischemia and reperfusion injury | |
| Ahmad et al. | Blunting of estrogen modulation of cardiac cellular chymase/RAS activity and function in SHR | |
| Lu et al. | Ghrelin inhibited pressure overload–induced cardiac hypertrophy by promoting autophagy via CaMKK/AMPK signaling pathway | |
| L Chevalier | Mechanisms of fetal and neonatal renal impairment by pharmacologic inhibition of angiotensin | |
| Hamid et al. | A critical cytoprotective role of endogenous adrenomedullin in acute myocardial infarction | |
| Yao et al. | Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction | |
| Jiang et al. | Relationship between the contents of adrenomedullin and distributions of neutral endopeptidase in blood and tissues of spontaneously hypertensive rats | |
| US20140296143A1 (en) | Angiotensin-(1-7) As A Chemoprevention Agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090629 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090629 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111129 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120529 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130104 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130326 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130415 |